PP
AST

Paloma Partners’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Paloma Partners’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-143,800
Closed -$194K – 2176
2018
Q2 		$194K Buy
+143,800
New +$220K ﹤0.01% 1482
2015
Q4 		– Sell
-13,966
Closed -$54K – 2119
2015
Q3 		$54K Buy
+13,966
New +$64.1K ﹤0.01% 1549

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Paloma Partners's AST Position: Q3 2018 in Review

Paloma Partners sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2018, closing a stake of 143,800 shares — an estimated $194K sold.

Paloma Partners first reported a position in AST in Q3 2015 and held it in 2 quarters. The position peaked at $194K in Q2 2018. 54 funds tracked by Wall St. Rank hold AST as of Q3 2018.

  • Paloma Partners reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2018 after selling out during the quarter.
  • Paloma Partners sold 143,800 Asterias Biotherapeutics Inc. Series A shares in Q3 2018, an estimated $194K.
  • Paloma Partners first reported a position in Asterias Biotherapeutics Inc. Series A in Q3 2015 and held it in 2 quarters.
  • Paloma Partners's Asterias Biotherapeutics Inc. Series A position peaked at $194K in Q2 2018.
  • 54 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.